期刊文献+

人类免疫缺陷病毒Ⅰ型Tat基因真核表达载体的构建

Construction and in vitro expression of an eukaryotic Vector encoding HIV - 1 Tat.
下载PDF
导出
摘要 目的:构建人类免疫缺病毒Tat基因真核表达质粒,并研究该质粒在真核细胞中的有效表达。方法:以含有HIV-1全长基因的质粒pNL4—3为模板,通过PCR扩增HIV-1 Tat第一外显子,应用基因工程技术将扩增的基因片段插入真核表达质粒pCDNA3.1(+),构建重组真核表达质粒pCDNA3.1-tat,经限制性内切酶酶切分析及测序鉴定正确后,应用脂质体转染技术转染入huh-7细胞。RT—PCR检测其基因转录情况,WesternBlot鉴定其是否能够表达相应的目的蛋白质。结果:成功扩增了Tat基因,酶切和测序证明正确构建了重组真核表达质粒pCDNA3.1-tat,RT—PCR证实该质粒能在huh-7真核细胞中有效表达Hiv-1Tat目的片段。结论:成功构建了HIV—ITat基因的真核表达质粒载体,并在huh-7中表达,为在huh-7细胞模型中研究Tat的功能奠定了基础。 Objective: To construct an eukaryotic plasmid expressing HIV- 1 Tat and test whether the plasmid can be expressed in the eukaryotic cell in vitro. Methods :The first exon of HIV - 1 Tat was amplified by PCR from the plasmid pNL4 - 3. Then the Tat gene was in- serted into the eukaryotie expression plasmid pCDNA3. 1 ( + ) , and the resultant recombinant plasmid was confirmed by restriction endonu- clease and sequencing , then was designated as pCDNA3.1 - tat. The recombinant plasmid pCDNA3.1 - tat was transfeeted into eukaryot- ie cell huh - 7 by lipo - fectamine. RT - PCR was used to certify whether the purpose protein was correctly expressed in huh - 7 cells. Results The 240 bp DNA fragment of tat was correctly amplified. The recombinant pCDNA3.1 - tat was successfully constructed , and it could be correctly expressed in the huh - 7 cells. Conclusions : This recombinant plasmid pCDNA3.1 - tat and the resulting huh - 7 cell model pro- vide a basis for further study on the function of HIV - 1 Tat .
作者 梁庄万
出处 《医学信息(下旬刊)》 2010年第3期16-17,共2页 Medical information
关键词 TAT基因 载体构建 HUH-7细胞 表达 Tat Vector Construction huh-7 Expression
  • 相关文献

参考文献13

  • 1Jeang KT,Xiao H,Rich EA.Multifaceted activities of the H IV-1 transactivator of transcrip tion,Tat[J].J B iol Chem,(Review).
  • 2Dandekar DH,Ganesh KN,Mitra D.H IV21 Tat directly binds toNFkappaB enhancer sequence:role in viral and cellular gene exp res2sion[J].N ucleic Acids Res,2004,32 (4):1270-1278.
  • 3崔凡,刘维达.HIV-1转录调控机制的研究进展[J].国外医学(皮肤性病学分册),2003,29(2):123-126. 被引量:8
  • 4Brigati C,GiaccaM,Noonan DM,et al.H IV Tat,its TARgets and the control of viral gene exp ression[J].FEMS M icrobiol Lett,2003,220 (1):57-65.
  • 5RusnatiM,Tulipano G,Urbinati C,et al.The basic domain in H IV21 Tat p rotein as a target for polysulfonated heparin2mimicking extracel2lular Tat antagonists[J].J B iol Chem,1998,273 (26):16027 -16037.
  • 6Ziegler A,Seelig J.Interaction of the p rotein transduction domain ofH IV21 TAT with heparan sulfate:bindingmechanism and thermody2namic parameters[J].B iophys J,2004,86 (1 Pt 1):254-263.
  • 7Verucchi G,Calza L,Redi RM,et al.Human Immunodeficiency Virus and Hepatitis C Virus Coinfection:Epidemiology,Natural History,Therapeutic Options and Clinical Management[J].Infection 2004,32(1):3-46.
  • 8Monga HK,Rodriguez-Barradas MC,Breaux K,et al.Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection[J].Infect Dis,2001,33:240-247.
  • 9RubartelliA,PoggiA,Sitia R,et al.H IV2I Tat:a polypep tide for allseasons[J].Imm unol Today,1999,20 (8):384-385.
  • 10曾怡,卢春.HIV-1 Tat协同HHV-6感染激活HHV-8增殖周期复制[J].中华微生物学和免疫学杂志,2005,25(4):337-337. 被引量:4

二级参考文献27

  • 1Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus:a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infec Dis,2002,34:831-837.
  • 2Zhang L, Cao Y, Yu J, et al. Outbreak of HIV- 1 and HCV infection among illegal blood donors in Henan province, China, Washington State Convention and Trade Center, Seattle, WA,2002.24-28.
  • 3Dragon F, CafoUa A, Giuseppe G, et al. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica,1999,84 : 525-529.
  • 4Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infec Dis, 2000,30 ( suppl 1 ) : s77- s84.
  • 5Greene WC, Peterlin BM. Charting HIV;s remarkable voyage throughthe cell: Basic science as a passport to future therapy. Nat Med. 2002, 8(7) :673 -680.
  • 6Majello B, Napo1litano G, De Luca P, et al. Recruitment of human TBP selectively activates RNA polymerase Ⅱ TATA-dependent promoters. J Biol Chem. 1998, 273(26) :16509 -16516.
  • 7Zenzie-Gregory B, Sheridan P, Jones KA, etal. HIV - 1 core promoter lacks a simple initiator element but contains a bipartite activator at the transcription start site. J Biol Chem, 1993, 268 (21): 15823- 15832.
  • 8Sune C, Garcia-Blanco MA. Spl transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol. 1995,69(10) :6572 - 6576.
  • 9Kretzschmar M, Meisterernst M, Scheidereit C, et al. Transcriptional regulation of the HIV - 1 promoter by NF-kappa B in vitro. Genes Dev, 1992, 6(5) :761 -774.
  • 10Takada N, Sanda T, Okamoto H, et al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J Virol, 2002, 76 ( 16 ): 8019 - 8030.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部